Dyax Corp. (DYAX) announced after the close Tuesday that the FDA granted approval for KALBITOR for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. The stock is now up 0.91 on 99K shares.
Dyax Corp. traded to the downside for the bulk of Tuesday afternoon and finished lower by 0.23 at $3.50. The stock fell to a 2-week low.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.